A Phase 3 interventional study of Semaglutide and Tirzepatide in Obesity, Overweight and/or Obesity and Overweight, sponsored by Pfizer. Not yet recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
The purpose of this study is to learn about the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide. The study does not include people with diabetes.
Participants will be in the study for about 11 months.
Exclusion Criteria:
Participants will receive Semaglutide or Tirzepatide by Subcutaneous Injection.
Drug: Semaglutide · Drug: Tirzepatide
Participants will receive Berobenatide by Subcutaneous Injection.
Drug: Berobenatide
Participants will receive Semaglutide administered subcutaneously.
Participants will receive Tirzepatide administered subcutaneously.
Participants will receive berobenatide solution for injection as subcutaneous injection.
Also known as: MET097, PF-08653944
Percent change from baseline in body weight
Time frame: Baseline, Week 32
Change from baseline in body weight
Time frame: Baseline, Week 32
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time frame: Baseline, Week 32
Number of Participants with Serious adverse events (SAEs)
Time frame: Baseline, Week 32
Number of Participants with adverse events leading to discontinuation
Time frame: Baseline, Week 32
Number of Participants with Adverse Events of Special Interest (AESIs)
Time frame: Baseline, Week 32
Number of Participants with Clinical Laboratory Abnormalities
Time frame: Baseline, Week 32
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer